Another weight-loss drug, survodutide, being developed by Boehringer Ingelheim, a German drug company, and Zealand, has shown promising results in being able to treat a serious liver condition called metabolic dysfunction-associated steatohepatitis (MASH).

另一种减肥药 Survodutide 是由德国制药公司勃林格殷格翰和 Zealand 共同开发的，在治疗一种名为代谢功能障碍相关脂肪性肝炎 (MASH) 的严重肝病方面已显示出良好的效果。